Navigation Links
Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence

Aromatase Inhibitors drug, Femara given after 5 years of Tamoxifen therapy is found to give protection against occurrence of Breast cancer recurrence. Breast cancer is the second leading cause of cancer// in women. Breast cancer mostly occurs in post menopausal women and various risk factors are attributed for the occurrence of breast cancer.

Treatment of breast cancer initially involves removal of the entire breast or part of the breast with the cancer lump followed by Radiation therapy and Chemotherapy. Cytotoxic drugs are given as chemotherapy for patients with breast cancer; usually 6 cycles of chemotherapeutic drugs are given such as Cyclophosphamide, 5 flurouracil, adiramycin. After these procedures 5 years of Tamoxifen therapy is recommended for post menopausal women. Tamoxifen therapy is recommended only for 5 years as studies in which tamoxifen given for more than 5 years shows no difference. Tamoxifen acts as an anti-estrogen by which it competitively inhibits the estrogens produced by the body, as estrogen is used up by the cancer cell for its growth and production. Metastasis and recurrence occurs in some cancer patients, though the chance of metastasis is very less as only 1 in 10000 cells has the capacity to reach the blood stream and cause cancer in a new organ.

Recurrence mostly occurs due to pitfalls or not properly taking therapy or tablets, even tamoxifen resistance developed by the patient may also lead to recurrence. Recurrence may occur at the same initial cancer site called as loco-regional or in a new site.

The new study using Femara Aromatase Inhibitors after 5 years of Tamoxifen therapy as found to give protection against occurrence of recurrence. Aromatase inhibitors lower the levels of estrogen in the body by acting on the Aromatase enzyme involved in making estrogen. The study was conducted in 5000 postmenopausal women who have finished their 5 years tamoxifen therapy and they were given femara for an other
'"/>




Page: 1 2

Related medicine news :

1. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
2. Early Switch to an Aromatase Inhibitor Increases Survival
3. LipB Protein Inhibitors Help To Fight Against TB
4. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
5. ACE Inhibitors For Vascular Disease Patients
6. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
7. Femara: The Wonder Drug to Prevent Relapse of Breast Cancer.
8. Thyroid hormone treatment hastens recovery after cardiac surgery
9. Morning after pill effective up to five days after having unprotected sex
10. Liver donors can thrive after transplant
11. Recouping blood flow after a stroke

Post Your Comments:
(Date:11/9/2009)...v. 9 Sutter Health, a family of do...are service providers, is donating $255,000 to foo...ocal food banks will share the quarter-million-dol...tables of thousands of families across the north s...partnering with and supporting charitable programs...
(Date:11/9/2009)...s with drugs that inhibit estrogen, , ,... to treat breast cancer and osteoporosis eliminate...y. , The drugs also cleared precancerous growth...t of cancer in mice with precancerous lesions. ,...t cancer/osteoporosis drug raloxifene were given t...
(Date:11/9/2009)... both eye conditions are age-related, researchers ...-- Cataract surgery doesn,t appear to speed the pr...), according to a new study that challenges the be...s the other. , "Because both conditions are str...also have AMD," wrote Li Ming Dong, of Stony Brook...
(Date:11/9/2009)...9 /PRNewswire-FirstCall/ - Hard To Treat Diseases ...hat Novartis, a US$41 billion international health...1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmac... Switzerland will begin a five-year, $1 billion Ch...matically increase its investment in its China R&a...
(Date:11/9/2009)...sive Cancer Network (NCCN) has posted a draft whit...radigm for near-term comparative effectiveness cli...cument introduces the NCCN Comparative Therapeutic...ompares the risk-versus-benefit of different treat...tice Guidelines in Oncology(TM). The paper will be...
Breaking Medicine News(10 mins):Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4
...hiladelphia, PA, June 25, 2007 State policies hav...y substance abuse treatment programs, and could pl...arch-based "comprehensive" treatment approaches, r...licy proscriptions emanating from scientific resea...
...tem cell research and the potential use of human e...oversial issue which splits both scientific and pu...stem cells throughout the world deals particularly...t. It is a symbolic struggle over the whole future...
...y dose of rivaroxaban cut risk of venous thromboem... (HealthDay News) -- Extended use of the oral drug... clots after hip replacement surgery, British res.... Current guidelines recommend patients receive a ...
...ARBOR, Mich., June 25 HealthMedia(R), Inc.,s,Succ...o-year Health,Information Products (HIP) Certifica...ance (NCQA), the most trusted source for informati...A, since responsibility for adherence to NCQA HRA ...
...cal Division Officer says " ... when we used Jelly...patients from the painful burning and stinging ...act.", SAVANNAH, Ga., June 25 Captain Kevin Carv...at provided,any true relief until he tried Jellyfi...
...R KNOLLS, N.J., June 25 MedeFile,International, I...zing in,portable electronic medical records manage...usive, membership only, resort community located i...ting of over 1,400 members., Members who subscrib...
Other Medicine News:Health News:State policies influence drug treatment programs 2Health News:Stem cell research from an ethical point of view 2Health News:Oral Drug Helps Prevent Clotting After Hip Replacement 2Health News:HealthMedia Health Risk Assessment Earns Prestigious NCQA Certification 2Health News:Okaloosa Island Fire Department Will Use Jellyfish Squish to Treat Jellyfish Stings 2Health News:Okaloosa Island Fire Department Will Use Jellyfish Squish to Treat Jellyfish Stings 3Health News:Exclusive Resort Community Looks to MedeFile to Provide Members With Access to Medical Records Anytime, Anywhere 2
(Date:11/9/2009)...RMINGHAM, Ala., Nov. 9 S...at it will host an investor conference call at 11:... to discuss its 2009 third quarter operating resul...ly an hour following the conclusion of the confere...gi-bin/prnh/20080812/CLTU111LOGO ) ,, Please...
(Date:11/9/2009)...DFORD, Mass., Nov. 9 Hol... ), a leading developer, manufacturer and supplier...nd surgical products dedicated to serving the heal... for the fourth quarter and fiscal year ended Sept...ed the Board of Directors has promoted Robert Casc...
(Date:11/9/2009)...ENWOOD, Ill., Nov. 9 La...n personal and environmental radiation monitoring ...quisitions in accordance with its long-term strate...the acquisitions of Global Physics Solutions, Inc....ll Saxelby, President and CEO of Landauer. "These ...
Breaking Medicine Technology:Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 2Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 3Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 4Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 5Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 6Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 7Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 8Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 9Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 10Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 11Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 12Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 13Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 14Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 15Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 16Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 17Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 18Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 19Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 20Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 21Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 22Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 23Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 24Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 25Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 26Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 27Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 28Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 2Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 3Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 4Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 5Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 50494 1Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 50494 2Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 50494 3Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 50494 4Human Genome Sciences to Host July 20 Conference Call to Discuss Top Line Phase 3 Results for Benlysta 28TM 29 28Formerly Lymphostat B 28R 29 29 in S 12863 1Human Genome Sciences to Host July 20 Conference Call to Discuss Top Line Phase 3 Results for Benlysta 28TM 29 28Formerly Lymphostat B 28R 29 29 in S 12863 2Siemens Hearing Instruments Introduces Affordable and Flexible Pure 300 50492 1Siemens Hearing Instruments Introduces Affordable and Flexible Pure 300 50492 2
Vitreoretinal Viscodissector 45 degrees
Infusion Cannula 6mm
Lacrimal Intubation Tubing
Replacment Tubing
Medicine Products: